AZD 1305

Known as: AZD-1305, AZD1305 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2016
01220092016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
INTRODUCTION Pharmacokinetic-pharmacodynamic (PKPD) modelling can improve safety assessment, but few PKPD models describing drug… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
The anesthetized chronic AV-blocked dog (cAVB) and methoxamine-sensitized rabbit model are widely used to determine pro… (More)
Is this relevant?
2012
2012
AIM AZD1305 is a novel, water-soluble investigational antiarrhythmic agent for restoration and maintenance of sinus rhythm in… (More)
Is this relevant?
2012
2012
The interest in hot-melt extrusion in the pharmaceutical industry has increased rapidly during the last years because of its many… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
AIM AZD1305 is a combined ion channel blocker developed for the treatment of atrial fibrillation (AF). The aim of this study was… (More)
Is this relevant?
2010
2010
Recent development of drugs for the treatment of atrial fibrillation (AF) has focused on atrial selective agents. We examined the… (More)
Is this relevant?
2010
2010
AIMS To assess the late Na+ current (INalate) blockade by the combined ion channel blocker AZD1305 and its influence on… (More)
Is this relevant?
2010
2010
BACKGROUND This study assessed the cardiac electrophysiological and hemodynamic effects of an intravenous infusion of the… (More)
Is this relevant?
2009
2009
AZD1305 is a novel antiarrhythmic agent under clinical evaluation for management of atrial fibrillation. This study assessed its… (More)
Is this relevant?
2009
2009
This randomized, double-blind trial compared cardioversion rates between AZD7009 infusion (15-minute 3.25 mg/min, 15-minute 4.4… (More)
Is this relevant?